Cox regression analysis: hazard ratio of JAK2 V617F mutation for different outcomes
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Univariate | ||
| Death from leukemic transformation | 4.0 (1.1-14.8) | .04 |
| Leukemic transformation | 3.7 (1.4-10.3) | .01 |
| Need of splenectomy | 3.5 (1.5-8.0) | <.05 |
| Death from all causes | 2.5 (1.0-6.2) | <.05 |
| Development of large splenomegaly | 2.0 (1.1-3.5) | .01 |
| Development of thrombocytopenia | 1.9 (0.8-4.5) | .14 |
| Major thrombosis | 1.7 (0.5-5.5) | .34 |
| Development of severe anemia | 1.3 (0.7-2.7) | .38 |
| Development of leukopenia | 0.7 (0.3-1.6) | .41 |
| Adjusted | ||
| Death from leukemic transformation | 3.2 (0.8-12.1) | .09 |
| Leukemic transformation | 5.2 (1.6-16.8) | <.01 |
| Need of splenectomy | 2.9 (1.2-6.8) | .01 |
| Death from all causes | 2.3 (0.8-6.1) | .10 |
| Development of large splenomegaly | 1.7 (1.0-3.0) | .05 |
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Univariate | ||
| Death from leukemic transformation | 4.0 (1.1-14.8) | .04 |
| Leukemic transformation | 3.7 (1.4-10.3) | .01 |
| Need of splenectomy | 3.5 (1.5-8.0) | <.05 |
| Death from all causes | 2.5 (1.0-6.2) | <.05 |
| Development of large splenomegaly | 2.0 (1.1-3.5) | .01 |
| Development of thrombocytopenia | 1.9 (0.8-4.5) | .14 |
| Major thrombosis | 1.7 (0.5-5.5) | .34 |
| Development of severe anemia | 1.3 (0.7-2.7) | .38 |
| Development of leukopenia | 0.7 (0.3-1.6) | .41 |
| Adjusted | ||
| Death from leukemic transformation | 3.2 (0.8-12.1) | .09 |
| Leukemic transformation | 5.2 (1.6-16.8) | <.01 |
| Need of splenectomy | 2.9 (1.2-6.8) | .01 |
| Death from all causes | 2.3 (0.8-6.1) | .10 |
| Development of large splenomegaly | 1.7 (1.0-3.0) | .05 |
*Hazard ratios were adjusted for age, sex, hemoglobin level, white blood cell count, percentage of blasts in peripheral blood, and Dupriez risk score.